[go: up one dir, main page]

WO1999036094A3 - Composition and method for treating metastatic tumors or cancer induced by cells expressing sv40 tumor antigen - Google Patents

Composition and method for treating metastatic tumors or cancer induced by cells expressing sv40 tumor antigen Download PDF

Info

Publication number
WO1999036094A3
WO1999036094A3 PCT/US1999/000827 US9900827W WO9936094A3 WO 1999036094 A3 WO1999036094 A3 WO 1999036094A3 US 9900827 W US9900827 W US 9900827W WO 9936094 A3 WO9936094 A3 WO 9936094A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumor antigen
composition
cells expressing
metastatic tumors
treating metastatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/000827
Other languages
French (fr)
Other versions
WO1999036094A2 (en
WO1999036094A9 (en
Inventor
Ronald C Kennedy
Allison M Watts
Michael H Shearer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Oklahoma
Original Assignee
University of Oklahoma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Oklahoma filed Critical University of Oklahoma
Priority to AU22282/99A priority Critical patent/AU2228299A/en
Publication of WO1999036094A2 publication Critical patent/WO1999036094A2/en
Publication of WO1999036094A9 publication Critical patent/WO1999036094A9/en
Publication of WO1999036094A3 publication Critical patent/WO1999036094A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)

Abstract

A prophylactic and therapeutic method for vaccinating and treating a mammal against metastatic tumors comprising cells which express large SV40 tumor antigen. The disclosure further describes an experimental murine pulmonary model for metastatic cancer and a method for quantitatively and automatically analyzing metastatic tumor foci.
PCT/US1999/000827 1998-01-14 1999-01-13 Composition and method for treating metastatic tumors or cancer induced by cells expressing sv40 tumor antigen Ceased WO1999036094A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU22282/99A AU2228299A (en) 1998-01-14 1999-01-13 Composition and method for treating metastatic tumors or cancer induced by cellsexpressing sv40 tumor antigen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7132798P 1998-01-14 1998-01-14
US60/071,327 1998-01-14

Publications (3)

Publication Number Publication Date
WO1999036094A2 WO1999036094A2 (en) 1999-07-22
WO1999036094A9 WO1999036094A9 (en) 1999-10-14
WO1999036094A3 true WO1999036094A3 (en) 1999-11-18

Family

ID=22100631

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/000827 Ceased WO1999036094A2 (en) 1998-01-14 1999-01-13 Composition and method for treating metastatic tumors or cancer induced by cells expressing sv40 tumor antigen

Country Status (2)

Country Link
AU (1) AU2228299A (en)
WO (1) WO1999036094A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8748371B2 (en) * 2007-02-28 2014-06-10 Yeda Research And Development Co. Ltd. Nuclear targeting sequences
WO2015040609A1 (en) 2013-09-17 2015-03-26 Yeda Research And Development Co. Ltd. Erk-derived peptides and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995004281A1 (en) * 1993-07-27 1995-02-09 THE UNITED STATES GOVERNMENT, represented by THE ADMINISTRATOR OF THE NATIONAL AERONAUTICS AND SPACE ADMINISTRATION Quantitative method of measuring cancer cell urokinase and metastatic potential
WO1995016051A2 (en) * 1993-12-03 1995-06-15 Board Of Regents, The University Of Texas System Methods and compositions for the suppression of neu mediated transformation
DE4433123C1 (en) * 1994-09-16 1996-03-28 Fraunhofer Ges Forschung Optical diagnostic appts. for body tissues or samples
WO1997043732A1 (en) * 1996-05-10 1997-11-20 Oncometrics Imaging Corp. Method and apparatus for automatically detecting malignancy-associated changes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995004281A1 (en) * 1993-07-27 1995-02-09 THE UNITED STATES GOVERNMENT, represented by THE ADMINISTRATOR OF THE NATIONAL AERONAUTICS AND SPACE ADMINISTRATION Quantitative method of measuring cancer cell urokinase and metastatic potential
WO1995016051A2 (en) * 1993-12-03 1995-06-15 Board Of Regents, The University Of Texas System Methods and compositions for the suppression of neu mediated transformation
DE4433123C1 (en) * 1994-09-16 1996-03-28 Fraunhofer Ges Forschung Optical diagnostic appts. for body tissues or samples
WO1997043732A1 (en) * 1996-05-10 1997-11-20 Oncometrics Imaging Corp. Method and apparatus for automatically detecting malignancy-associated changes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A. WATTS ET AL.: "Recombinant SV40 T-Ag immunization provides tumor immunity in an experimental pulmonary metastasis model.", THE FASEB JOURNAL, vol. 12, no. 4, 17 March 1998 (1998-03-17), BETHESDA, MD, USA, pages A279, XP002112235 *
M. SHEARER ET AL.: "Immunization of mice with baculovirus-derived recombinant SV40 large tumour antigen induces protective tumour immunity to a lethal challenge with SV40-transformed cells.", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 91, 1993, pages 266 - 271, XP002037402 *
R. BRIGHT ET AL.: "Immunization of BALB/c mice with recombinant simian virus 40 large tumor antigen induces antibody-dependent cell-mediated cytotoxicity against simian virus 40-transformed cells.", THE JOURNAL OF IMMUNOLOGY, vol. 153, no. 5, 1 September 1994 (1994-09-01), BALTIMORE, MD, USA, pages 2064 - 2071, XP002112234 *
R. BRIGHT ET AL.: "Protection against a lethal tumor challenge with SV40-transformed cells by the direct injection of DNA-encoding SV40 large tumor antigen.", CANCER RESEARCH, vol. 56, no. 5, 1 March 1996 (1996-03-01), BALTIMORE, MD, USA, pages 1126 - 1130, XP002112233 *

Also Published As

Publication number Publication date
AU2228299A (en) 1999-08-02
WO1999036094A2 (en) 1999-07-22
WO1999036094A9 (en) 1999-10-14

Similar Documents

Publication Publication Date Title
AU3865899A (en) Apparatus and methods for the penetration of tissue, and the creation of an opening therein
AU6266899A (en) Methods for producing human tumor antigen specific antibodies
MXPA01009645A (en) Human antibodies that bind human il-12 and methods for producing.
ZA99693B (en) Compounds for therapy and diagnosis of lung cancer and methods for their use.
EP1239874A4 (en) Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
WO2002080754A3 (en) Methods for using annexin for detecting cell death in vivo and treating associated conditions
MXPA03003151A (en) Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer.
AU4085097A (en) Methods and kits for obtaining and assaying mammary fluid samples for breast diseases, including cancer
IS4456A (en) Coconut extract that inhibits tumors and methods for making and using it
ZA99452B (en) Antibodies against human IL-12.
AU7380500A (en) Methods for treating tumors using neutron therapy
WO1997008318A3 (en) Compounds and methods for treatment and diagnosis of prostate cancer
WO2000029574A3 (en) Inflammation-associated genes
AU2001250932A1 (en) Compositions and methods of diagnosing, monitoring, staging, imaging and treating prostate cancer
AU2001251084A1 (en) Polynucleotides and polypeptides as well as methods for diagnosing and treating lung cancer
WO2002078516A3 (en) Compositions and methods for the therapy and diagnosis of cancer
EP1131095A4 (en) Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
IL142340A0 (en) Methods for identification, diagnosis, and treatment of breast cancer
IL147749A0 (en) Methods for treating therapy-resistant tumors
WO2003013431A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
EP1072272A4 (en) Method for producing a specific antiserum against the universal tumorous antigen and method for diagnosing malignant tumours using said antiserum
FI953534L (en) Method for identifying and treating individuals with cancer cells expressing HLA-C clone 10/MAGE-1
WO1999036094A3 (en) Composition and method for treating metastatic tumors or cancer induced by cells expressing sv40 tumor antigen
AU2001241656A1 (en) Methods for diagnosing, monitoring, staging, imaging and treating lung cancer via lung cancer specific genes
AU2001268633A1 (en) Method of diagnosing, monitoring, staging, imaging and treating breast cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGE 6/8, DRAWINGS, REPLACED BY A NEW PAGE 6/8; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: KR

122 Ep: pct application non-entry in european phase